Compare Amylx Pharmaceuticals Inc (AMLX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs NEOS S&P 500 High Income ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while NEOS S&P 500 High Income ETF trades at $53.62. Which is the better fit depends on your goals.
| AMLX | SPYI | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $18.70 | $54.07 |
52-Week Low | $7.64 | $47.98 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SPYI trades at $53.70, up 0.36% on the day, with a bullish technical signal driven by moving averages and strong support at $53. The ETF has grown to over $10 billion in assets, highlighted by consistent monthly dividends and a yield near 12%. Recent news emphasizes its appeal for income-focused investors seeking S&P 500 exposure with reduced volatility.
Outlook remains positive due to robust investor inflows and a covered-call strategy that balances income with upside participation. Key risks include fee erosion over time and market sensitivity, but SPYI's diversification and high yield position it as a core holding for retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
